Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single‐blind, placebo‐controlled study in F2/F3 NASH

Abstract Rencofilstat (RCF) demonstrated antifibrotic effects in preclinical models and was safe and well tolerated in Phase 1 studies. The aim of this Phase 2a study was safety, tolerability, pharmacokinetics, and exploration of efficacy biomarkers in subjects with nonalcoholic steatohepatitis (NAS...

Full description

Bibliographic Details

Published in:	Hepatology Communications
Main Authors:	Stephen A. Harrison, Patrick R. Mayo, Todd M. Hobbs, Carlos Canizares, Erin P. Foster, Caroline Zhao, Daren R. Ure, Daniel J. Trepanier, Jill A. Greytok, Robert T. Foster
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2022-12-01
Online Access:	https://doi.org/10.1002/hep4.2100